{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:59:51Z","timestamp":1790913591371,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00645","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T09:09:44Z","timestamp":1560244184000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient"],"prefix":"10.3389","volume":"10","author":[{"given":"Tim","family":"B\u00fchler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Medinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Bouitbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Leuppi-Taegtmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob Chemother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clpt.2006.02.012","article-title":"Drug-induced liver injury: Hy\u2019s rule revisited","volume":"79","author":"Bjornsson","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2165\/00003495-200464180-00001","article-title":"Newer systemic antifungal agents: pharmacokinetics, safety and efficacy","volume":"64","author":"Boucher","year":"2004","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.5694\/j.1326-5377.2007.tb01313.x","article-title":"Antifungal agents","volume":"187","author":"Chen","year":"2007","journal-title":"Med. J. Aust."},{"key":"B6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/myc.12318","article-title":"Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens","volume":"58","author":"Corzo-Leon","year":"2015","journal-title":"Mycoses"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9658018","article-title":"Hepatotoxicity of antimycotics used for invasive fungal infections: in vitro results","volume":"2017","author":"Doss","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"B8","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/clinchem\/46.12.2050","article-title":"Diagnosis and monitoring of hepatic injury","volume":"46","author":"Dufour","year":"2000","journal-title":"Clin. Chem."},{"key":"B9","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/clinchem\/46.12.2027","article-title":"Diagnosis and monitoring of hepatic injury","volume":"46","author":"Dufour","year":"2000","journal-title":"Clin. Chem."},{"key":"B10","article-title":"The pharmacokinetic properties of posaconazole in faster healthy subjects: basis for clinical dosage recommendations","volume-title":"42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Ezzet","year":"2002"},{"key":"B11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1086\/521174","article-title":"Lack of cross-hepatotoxicity between voriconazole and posaconazole","volume":"45","author":"Foo","year":"2007","journal-title":"Clin. Infect Dis."},{"key":"B12","volume-title":"Vfend Prescribing Information","year":"2010"},{"key":"B13","volume-title":"Cresemba Prescribing Information","year":"2015"},{"key":"B14","volume-title":"Noxafil Prescribing Information","year":"2015"},{"key":"B15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1503\/cmaj.1040752","article-title":"Liver enzyme alteration: a guide for clinicians","volume":"172","author":"Giannini","year":"2005","journal-title":"CMAJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0891-5520(02)00068-5","article-title":"Clinical pharmacology of antifungal compounds","volume":"17","author":"Groll","year":"2003","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/toxsci\/kfx029","article-title":"Hepatocellular toxicity of imidazole and triazole antimycotic agents","volume":"157","author":"Haegler","year":"2017","journal-title":"Toxicol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/toxsci\/kfv319","article-title":"Low dose acetaminophen induces reversible mitochondrial dysfunction associated with transient c-Jun N-terminal kinase activation in mouse liver","volume":"150","author":"Hu","year":"2016","journal-title":"Toxicol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jhep.2018.05.013","article-title":"Pharmacogenomics of drug-induced liver injury (DILI): molecular biology to clinical applications","volume":"69","author":"Kaliyaperumal","year":"2018","journal-title":"J. Hepatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1021\/acs.chemrestox.7b00065","article-title":"Supernatant from hepatocyte cultures with drugs that cause idiosyncratic liver injury activates macrophage inflammasomes","volume":"30","author":"Kato","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14740338.2017.1270264","article-title":"Clinical hepatotoxicity associated with antifungal agents","volume":"16","author":"Kyriakidis","year":"2017","journal-title":"Expert Opin. Drug. Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B24","unstructured":"BethesdaFood and Drug Administration"},{"key":"B25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.amjmed.2015.10.029","article-title":"Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status","volume":"129","author":"Lo Re","year":"2016","journal-title":"Am. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1124\/dmd.109.027292","article-title":"Bioactivation of minocycline to reactive intermediates by myeloperoxidase, horseradish peroxidase, and hepatic microsomes: implications for minocycline-induced lupus and hepatitis","volume":"37","author":"Mannargudi","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"B28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hep.26077","article-title":"Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury","volume":"57","author":"Monshi","year":"2013","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/FTD.0000000000000524","article-title":"Validation of an isavuconazole high-performance liquid chromatography assay in plasma for routine therapeutic drug monitoring applications","volume":"40","author":"Mueller","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"B30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/toxsci\/kfx069","article-title":"Characterization of drug-specific signaling between primary human hepatocytes and immune cells","volume":"158","author":"Ogese","year":"2017","journal-title":"Toxicol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.4254\/wjh.v6.i8.601","article-title":"Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database","volume":"6","author":"Raschi","year":"2014","journal-title":"World J. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40264-018-0743-2","article-title":"Drug-induced liver injury: highlights of the recent literature","volume":"42","author":"Real","year":"2019","journal-title":"Drug Saf"},{"key":"B35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/hep.20081","article-title":"Hy\u2019s law","volume":"39","author":"Reuben","year":"2004","journal-title":"Hepatology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/(SICI)1522-7146(1996)11:3<127::AID-JBT4>3.0.CO;2-M","article-title":"Inhibition of mitochondrial function in isolated rate liver mitochondria by azole antifungals","volume":"11","author":"Rodriguez","year":"1996","journal-title":"J. Biochem Toxicol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1124\/jpet.116.237578","article-title":"Idiosyncratic drug-induced liver injury: is drug-cytokine interaction the Linchpin","volume":"360","author":"Roth","year":"2017","journal-title":"J. Pharmacol Exp. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/374255","article-title":"Lack of cross-hepatotoxicity between fluconazole and voriconazole","volume":"36","author":"Spellberg","year":"2003","journal-title":"Clin. Infect Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.xphs.2017.03.023","article-title":"Model systems for studying the role of canalicular efflux transporters in drug-induced cholestatic liver disease","volume":"106","author":"Stieger","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00188-17","article-title":"Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses","volume":"61","author":"Tverdek","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jhep.2017.03.010","article-title":"Minocycline hepatotoxicity: clinical characterization and identification of HLA-B *35:02 as a risk factor","volume":"67","author":"Urban","year":"2017","journal-title":"J. Hepatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12941-019-0311-3","article-title":"Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center","volume":"18","author":"Van Matre","year":"2019","journal-title":"Ann. Clin. Microbiol Antimicrob."},{"key":"B43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2230.2010.03967.x","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking","volume":"36","author":"Walsh","year":"2011","journal-title":"Clin. Exp. Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin. Infect Dis."},{"key":"B45","volume-title":"Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. edn","author":"Zimmerman","year":"1999"},{"key":"B46","unstructured":"Ulm: The ZKRD. The German National Bone Marrow Donor Registry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00645\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T05:50:48Z","timestamp":1608270648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00645\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":46,"alternative-id":["10.3389\/fphar.2019.00645"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00645","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"article-number":"645"}}